Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleNEUROPHARMACOLOGY

Mixed Cocaine Agonist/Antagonist Properties of (+)-Methyl 4β-(4-Chlorophenyl)-1-methylpiperidine-3α-carboxylate, a Piperidine-Based Analog of Cocaine

Alan P. Kozikowski, Kenneth M. Johnson, Olivier Deschaux, Bidhan C. Bandyopadhyay, Gian Luca Araldi, Gilberto Carmona, Patrik Munzar, Miles P. Smith, Robert L. Balster, Patrick M. Beardsley and Srihari R. Tella
Journal of Pharmacology and Experimental Therapeutics April 2003, 305 (1) 143-150; DOI: https://doi.org/10.1124/jpet.102.046318
Alan P. Kozikowski
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kenneth M. Johnson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Olivier Deschaux
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bidhan C. Bandyopadhyay
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gian Luca Araldi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gilberto Carmona
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patrik Munzar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Miles P. Smith
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert L. Balster
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patrick M. Beardsley
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Srihari R. Tella
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The present study investigated the pharmacological properties of a piperidine-based novel cocaine analog, namely, (+)-methyl 4β-(4-chlorophenyl)-1-methylpiperidine-3α-carboxylic acid [(+)-CPCA]. Like cocaine, (+)-CPCA inhibited rat synaptosomal dopamine and norepinephrine uptake with high affinity, but was 33-fold less potent than cocaine in inhibiting serotonin uptake. Like cocaine, (+)-CPCA is a locomotor stimulant, although it was less potent and efficacious than cocaine. Importantly, pretreatment with (+)-CPCA dose dependently blocked the locomotor stimulant effects of cocaine in rats. (+)-CPCA completely substituted for cocaine in drug discrimination tests, although it was about 3 times less potent than cocaine. It was also self-administered by rats. Unexpectedly, (+)-CPCA did not enhance cocaine-induced convulsions in mice. As expected from rodent studies, rhesus monkeys readily self-administered (+)-CPCA. However, compared with cocaine, (+)-CPCA showed limited reinforcing properties in rats as assessed by both fixed and progressive ratio intravenous drug self-administration tests. These results collectively suggest that (+)-CPCA has an atypical pharmacological profile having both cocaine-like “agonist” and some cocaine “antagonist” properties. These properties of (+)-CPCA suggest that it may have utility in the treatment of cocaine craving and dependence.

Footnotes

  • This work was supported by a grant from the National Institute on Drug Abuse and in part by the National Institute of Mental Health Psychoactive Drug Screening Program (NO1MH80005).

  • DOI: 10.1124/jpet.102.046318

  • Abbreviations:
    DAT
    dopamine transporter
    SERT
    serotonin transporter
    (+)-CPCA
    (+)-methyl 4β-(4-chlorophenyl)-1-methylpiperidine-3α-carboxylic acid
    5-HT
    5-hydroxytryptamine, serotonin
    GBR12909
    1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine
    • Received November 1, 2002.
    • Accepted December 6, 2002.
  • U.S. Government
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 305 (1)
Journal of Pharmacology and Experimental Therapeutics
Vol. 305, Issue 1
1 Apr 2003
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Mixed Cocaine Agonist/Antagonist Properties of (+)-Methyl 4β-(4-Chlorophenyl)-1-methylpiperidine-3α-carboxylate, a Piperidine-Based Analog of Cocaine
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleNEUROPHARMACOLOGY

Mixed Cocaine Agonist/Antagonist Properties of (+)-Methyl 4β-(4-Chlorophenyl)-1-methylpiperidine-3α-carboxylate, a Piperidine-Based Analog of Cocaine

Alan P. Kozikowski, Kenneth M. Johnson, Olivier Deschaux, Bidhan C. Bandyopadhyay, Gian Luca Araldi, Gilberto Carmona, Patrik Munzar, Miles P. Smith, Robert L. Balster, Patrick M. Beardsley and Srihari R. Tella
Journal of Pharmacology and Experimental Therapeutics April 1, 2003, 305 (1) 143-150; DOI: https://doi.org/10.1124/jpet.102.046318

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleNEUROPHARMACOLOGY

Mixed Cocaine Agonist/Antagonist Properties of (+)-Methyl 4β-(4-Chlorophenyl)-1-methylpiperidine-3α-carboxylate, a Piperidine-Based Analog of Cocaine

Alan P. Kozikowski, Kenneth M. Johnson, Olivier Deschaux, Bidhan C. Bandyopadhyay, Gian Luca Araldi, Gilberto Carmona, Patrik Munzar, Miles P. Smith, Robert L. Balster, Patrick M. Beardsley and Srihari R. Tella
Journal of Pharmacology and Experimental Therapeutics April 1, 2003, 305 (1) 143-150; DOI: https://doi.org/10.1124/jpet.102.046318
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Oxysterols and ethanol
  • P-glycoprotein Apical Efflux Ratio for Compound Optimization
  • Pharmacology of Carbamate Insecticides at MT1 & MT2
Show more Neuropharmacology

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics